Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer

Inclusion Criteria: * Patients with histologically proven cervical carcinoma (All histological subtype will be included). * Patients who have stage IVB, recurrent or persistent disease. * Patients who are not amenable to curative treatment with surgery and/or radiotherapy. * Patients who have not received chemotherapy or chemoradiotherapy after diagnosis of recurrent, persistent, or stage IVB disease. * If the patient have received chemotherapy, radiotherapy or chemoradiotherapy as previous treatment, following interval must have elapsed from the last administration of treatment: 1. Chemotherapy: 21 days 2. Radiotherapy: 21 days\* 3. Chemoradiotherapy: 42 days\* If there have been residual disease in previously irradiated field and without disease progression since the (chemo) radiotherapy, 90 days must have elapsed after the last administration of irradiation. * Patients who have adequate hematologic, hepatic and renal functions as defined below: * Hemoglobin: ≥ 8.0 g/dL * Neutrophil count: ≥ 2,000/mm\^3 * Platelet count: ≥ 100,000/mm\^3 * Total serum bilirubin: ≤ 1.5 times the upper limits of normal (ULN) * AST (GOT), ALT (GPT): ≤ 2.5 times the ULN. If abnormal values are associated with hepatic metastasis: ≤ 5.0 times the ULN * Serum creatinine: ≤ ULN or creatinine clearance: ≥ 50 ml/min * Patients who have an ECOG performance status : 0-1. * Age: ≥ 20 years old. * Patients who can take pills orally. * Patients who signed the written consent form. Exclusion Criteria: * Patients who have known hypersensitivity to 5-FU or Cisplatin. * Patients who are receiving concomitant treatment with drugs interacting with S-1. * Patients who are receiving concomitant treatment with drugs interacting with Cisplatin. * Patients who were administered other investigational products within 30 days before the initiation of study treatment. * Patients who were previously treated with S-1. * Patients who had received platinum-containing chemotherapy or chemoradiotherapy and whose disease progressed during the therapy. * Patients who suffer from active infection (e.g. fever ≥ 38°C). * Patients who have serious complications. * Patients with bleeding which requires hemostasis treatment. * Patients with bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage. * Patients with uncontrolled pleural effusion and/or ascites requiring drainage at least twice a week. * Patients with symptomatic brain metastasis or history of brain metastasis. * Patients who have unmanageable bowel movement (ex. Watery stool, chronic constipation). * Patients with active double cancer. * Patients who are pregnant or lactating. * Patients who are considered to be inappropriate to the subject of this study by the investigator.